Atlas Trials

Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma

Clinical trial NCT01456585 · COMPLETED

Trial details

NCT number
NCT01456585
Sponsor
Abramson Cancer Center at Penn Medicine
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Adenocarcinoma Pancreas
Start date
2012-04-01
Primary completion
2013-04-01
Enrollment
10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.